Vericiguat for endothelial dysfunction and CRT response in non-responders: the VERCET prospective observational study

20260 citationsJournal Articlegold Open Access

Authors

Celestino Sardu · Istituto Neurologico Mediterraneo

Ludovica Vittoria Marfella · University of Campania "Luigi Vanvitelli"

Luca Rinaldi · University of Campania "Luigi Vanvitelli"

Ferdinando Carlo Sasso · University of Campania "Luigi Vanvitelli"

Domenico Cozzolino · University of Campania "Luigi Vanvitelli"

Francesco Nappo · University of Campania "Luigi Vanvitelli"

Ausilia Sellitto

Abstract

Our findings demonstrate that vericiguat reduces ED and enhances the response to CRT in prior non-responders by significantly lowering inflammatory/oxidative stress markers and ET-1.

Topics & Keywords

Cardiovascular Function and Risk Factors Cardiovascular and exercise physiology Pulmonary Hypertension Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Medicine

DOI: 10.1186/s12916-026-04747-6

Field-Weighted Citation Impact: 0.00